NOVO-MEMANTINE TABLET

Pajjiż: Kanada

Lingwa: Ingliż

Sors: Health Canada

Ingredjent attiv:

MEMANTINE HYDROCHLORIDE

Disponibbli minn:

TEVA CANADA LIMITED

Kodiċi ATC:

N06DX01

INN (Isem Internazzjonali):

MEMANTINE

Dożaġġ:

10MG

Għamla farmaċewtika:

TABLET

Kompożizzjoni:

MEMANTINE HYDROCHLORIDE 10MG

Rotta amministrattiva:

ORAL

Unitajiet fil-pakkett:

30/100

Tip ta 'preskrizzjoni:

Prescription

Żona terapewtika:

MISCELLANEOUS CENTRAL NERVOUS SYSTEM AGENTS

Sommarju tal-prodott:

Active ingredient group (AIG) number: 0150423001; AHFS:

L-istatus ta 'awtorizzazzjoni:

CANCELLED PRE MARKET

Data ta 'l-awtorizzazzjoni:

2015-10-16

Karatteristiċi tal-prodott

1
PRODUCT MONOGRAPH
PR
NOVO-MEMANTINE
Memantine Hydrochloride Tablets 5 mg and 10 mg
N-methyl-D-aspartate (NMDA) receptor antagonist
Teva Canada Limited
30 Novopharm Court
Toronto, Ontario
M1B 2K9
Submission Control No: 121195, 174595
Date of Preparation:
July 7, 2014
2
NAME OF DRUG
Pr
NOVO-MEMANTINE
Memantine Hydrochloride Tablets 5 mg and 10 mg
THERAPEUTIC CLASSIFICATION
N-methyl-D-aspartate (NMDA) receptor antagonist
ACTION AND CLINICAL PHARMACOLOGY
Persistent
activation
of
the
central
nervous
system
N-methyl-D-aspartate
(NMDA)
receptors by the excitatory amino acid glutamate has been hypothesized
to contribute to
the
symptomatology
of
Alzheimer’s
disease.
Memantine
is
postulated
to
exert
its
therapeutic effect through its action as a low to moderate affinity
uncompetitive (open
channel) NMDA receptor antagonist, which binds preferentially to the
NMDA receptor-
operated cation channels. It blocks the effects of pathologically
elevated sustained levels
of glutamate that may lead to neuronal dysfunction. There is no
clinical evidence that
memantine prevents or slows neurodegeneration or alters the course of
the underlying
dementing process in patients with Alzheimer’s disease. Memantine
exhibits low to
negligible affinity for other receptors (GABA, benzodiazepine,
dopamine, adrenergic,
noradrenergic, histamine and glycine) or voltage-dependent Ca
2+
, Na
+
or K
+
channels. In
addition, it does not directly affect the acetylcholine receptor or
cholinergic transmission,
which have been implicated in the cholinomimetic side effects (e.g.,
increased gastric
acid
secretion,
nausea
and
vomiting)
seen
with
acetylcholinesterase
inhibitors.
Memantine showed antagonist effects at the 5HT
3
receptor with a potency similar to that
for the NMDA receptor.
In vitro studies have shown that memantine does not affect the
reversible inhibition of
acetylcholinesterase by donepezil or galantamine.
3
PHARMACOKINETICS
ABSORPTION
Orally administered memantine is completely absorbed. Oral
bioavailability is almost
100%. Time to maxi